Intellia Therapeutics secured a five-year senior secured Credit Facility of up to $400 million, including $75 million funded at closing. The financing gives Intellia funds for Working Capital and general corporate purposes, while further availability depends on FDA approval, Revenue milestones, Equity fundraising and agreement with lenders.
Key Highlights
- Intellia received $75 million through the initial term Loan at closing.
- Five additional tranches can provide up to $225 million, subject mainly to lonvo-z milestones.
- The facility requires at least $50 million in controlled-account Liquidity before FDA approval of lonvo-z.
The financing includes $75 million funded at closing and gives Intellia (NASDAQ: NTLA) access to additional capital tied to regulatory, revenue and equity milestones.
$75 Million Funded at Closing
The initial $75 million term loan was funded on September 4, 2026. Intellia can request another $75 million if the U.S. Food and Drug Administration approves its Biologics license application for lonvoguran ziclumeran, also known as lonvo-z, subject to a specified date. Three potential draws of $40 million each depend on revenue targets, while another $30 million draw depends on an equity fundraising target. An uncommitted incremental facility of up to $100 million requires mutual agreement between Intellia and the lenders. The credit facility matures on September 4, 2031, when all outstanding principal is due. Monthly interest is set at the greater of 3.00% or the one-month SOFR rate plus a 6.15% margin. Intellia must also pay commitment, administrative, undrawn-amount and facility fees.
Funding Tied to Milestones and Security
Proceeds are designated for Intellia’s working capital needs and general corporate purposes. The obligations are secured on a first-priority basis by substantially all company assets, including intellectual property, subject to specified exceptions. Before FDA approval of the lonvo-z BLA, Intellia must maintain at least $50 million in controlled-account liquidity. The agreement also requires Intellia to meet specified revenue or market-capitalization conditions, or hold outstanding loan principal in controlled-account cash equivalents. Restrictions cover additional indebtedness, liens, investments, acquisitions, mergers, asset sales, licensing transactions, dividends and certain agreement changes. Synthetic Royalty transactions are permitted under a specified exception, while payment defaults, covenant breaches, Insolvency and change-of-control events can accelerate repayment.




Please wait processing your request...